Hematological malignancies complicating β-thalassemia syndromes: a single center experience

TO THE EDITOR: Only few reports have addressed the occurrence of hematological malignancies in patients suffering from β-thalassemia. We herein report two patients with major and intermedia β-thalassemia who were complicated with Hodgkin’s lymphoma and chronic myelogenous leukemia (CML) during the course of the disease, respectively. This report indicate that malignancies should be suspected and kept in mind in patients with β-thalassemia syndromes presenting with proposed signs and symptoms including unexplained lymphadenopathy, leukocytosis and splenomegaly.

β-thalassemia major is a genetic hemoglobinopathy characterized by point mutations of β-globin chain resulting in accumulation and deposition of unpaired β-globin chains in red blood cell (RBC). This causes severe hemolysis and ineffective hematopoiesis leading to severe anemia [1]. Currently the availability of proper care and appropriate treatment strategies including regular transfusions, allogeneic stem-cell transplantation, inducers of fetal hemoglobin, and precise iron chelation therapy with desferrioxamine (DFO) and/or deferiprone (DFP) have resulted in increased life expectancy and quality of life of the patients suffering from β-thalassemia major [2-4]. This increased life span increases the possibility of occurrence of other diseases such as malignancies. Although, previously malignancies were considered rare in β-thalassemia patients, but currently the number of malignancies reported in thalassemic patients is increasing [5-9]. We herein, report two patients with β-thalassemia major and intermedia who developed Hodgkin’s lymphoma and chronic myelogenous leukemia (CML) during the course of the disease.

CASE 1
A 16-year-old girl with β-thalassemia major presented with painless bilateral cervical lymphadenopathies for 1 month. She had been on regular transfusion since 9 months of age and was HCV positive due to regular transfusions. Her parents were heterozygotes for β-thalassemia minor. Initial evaluations including complete blood count, biochemistry tests, Epstein barr virus infection (EBV) and toxoplasmosis studies were not conclusive. white blood cells and platelets were normal. serum ferritin levels of the patient were 3,200 ng/mL and 3,000 ng/mL at two occasions. She was receiving subcutaneous desferrioxamine at least 5 nights/week as iron chelation since 2.5 years of age. After about 3 weeks of persistent cervical lymphadenopathy, computerized tomography (CT) scan of the neck and chest was performed revealing bilateral cervical and upper anterior mediastinal lymph nodes with para-tracheal involvement. Abdominopelvic imaging was normal. An excisional lymph node biopsy was performed which was compatible with Hodgkin’s lymphoma, nodular sclerosis subtype. Clinical staging revealed stage 2A (spleen was considered enlarged due to thalassemia since it was not a new finding). She was scheduled to receive systemic chemotherapy with 6 alternating cycles of MOPP/ABVD followed by radiotherapy and was off-therapy thereafter. Her mother also developed colon adenocarcinoma 6 years later and her brother (who was hematologically normal) died of brain tumor 8 years later. She also received antiviral treatments including α-interferon and ribavirin for HCV and changed to be negative. Fortunately, the patient is in remission for Hodgkin’s lymphoma and still on regular blood transfusion after 10 years of follow-up.

CASE 2
A 13-year-old girl with β-thalassemia intermedia was referred to our clinic due to hyperleukocytosis (WBC: 154,000/mm³). She was receiving hydroxyurea since 8 years of age and had been kept transfusion independent. At presentation she had Hb 8.5–9 gr/dL, MCV 78 fl and MCH 20 pg. Hemoglobin electrophoresis revealed HbA 45%, Hbf 51% and HbA2 4%. Spleen was palpated about 4-cm below costal margin. Splenomegaly was evident as it was before. Due to the persistence of hyperleukocytosis (WBC: 50,000–150,000/mm³) and aggravation of anemia, a bone marrow aspiration was performed which showed
Discussion

In this brief article, we have presented two patients with thalassemia syndromes (β-thalassemia major and β-thalasse-
mia intermedia) who developed hematologic malignancies (Hodgkin’s lymphoma and CML) during the course of the
disease. A thorough review of the literature reveals that only few cases of major β-thalassemia complicated with
lymphoma has been reported [6, 8–10]. CML in a patient with β-thalassemia intermedia has not yet been reported.
Sallam and colleagues [7] reported a patient with sickle cell/beta thalassemia (β/S/β0) who was complicated with
CML. Several other studies have reported two patients with intermedia β-thalassemia who developed other hematol-
ogical malignancies including non-Hodgkin lymphoma [11, 12].

The occurrence of hematological malignancies such as leukemia and lymphoma in thalassemia patients could be
a pure coincidence or a combination of genetic and environmental factors. Previously, definite genetic link between
thalassemia syndromes and lymphoma has been rejected by Quattin and co-workers who reported comparable in-
cidence of leukemia in patients with β-thalassemia and general population [12]. It was further reported by Zurlo and
colleagues [13] that the most common cause of death in those with major β-thalassemia was heart disease, followed
by infection, liver disease, and malignancy. Currently there are few reports available and thus we cannot comment
on the relationship between malignancies and thalassemia syndromes.

In our report, immunomodulation due to multiple trans-
fusions could be considered as a probable predisposing factor in development of Hodgkin’s lymphoma in the patient with
major β-thalassemia. In addition since she was HCV positive, it could be also proposed as a putative agent. Another proba-
bility is familial cancer syndromes in this case as a predispos-
ing factor superimposed by acquired factors like immu-
nomodulation due to transfusion and viral factors such as HCV infection. The probable mechanisms for occurrence of
malignancy in the girl with β-thalassemia intermedia could be the same as general population or as a result of
prolonged treatment with hydroxyurea for at least 4 years. There is also a report in the literature of a patient with
sickle cell disease who developed acute myeloid leukemia after 2 years of hydroxyurea therapy [14]. The short interval
between treatment with hydroxyurea and occurrence of leukemia more strongly suggests of therapy-related leuke-
mia. Our first case had prolonged hyperferritinemia and also was receiving iron chelation treatment with desferiox-
amine for a long time. The effects of iron over load and treatment with iron chelating agents could be another hy-
pothesis for development of malignancies in these patients [15]; however, low incidence of malignancies still suggest
coincidental occurrence of these conditions and none of these theories could be confirmed unless prospective cohort
studies with large control groups are designed and per-
formed.

In conclusion, malignancies should be suspected and kept
in mind in the patients with β-thalassemia syndromes pre-
senting with new onset signs and symptoms including lymph-
adenopathy, leukocytosis and splenomegaly.

Samin Alavi1, Alieh Safari2, Elham Sadeghi3, Somayeh Amirí1

1Pediatric Congenital Hematologic Disorders Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran, 2Tehran University of Medical Science, Tehran, Iran, 3Thalassemia Comprehensive Center, Mofid Children’s Hospital, Shahid Beheshti Medical University, Tehran, Iran

Correspondence to: Samin Alavi
Pediatric Congenital Hematologic Disorders Research Center, Mofid Children’s Hospital, Shahid Beheshti University of Medical Sciences, PO Box 15468-15514, Tehran, Iran
E-mail: s.alavi@sbmu.ac.ir

Received on Feb. 7, 2013; Revised on May 28, 2013; Accepted on May 28, 2013
http://dx.doi.org/10.5045/br.2013.48.2.149

Authors’ Disclosures of Potential Conflicts of Interest
No potential conflicts of interest relevant to this article were reported.

References
1. Rund D, Rachmilewitz E. Beta-thalassemia. N Engl J Med 2005;
353:1135–46.
2. Telfer P. Update on survival in thalassemia major. Hemoglobin
2009;33:576–80.
3. Chaidos A, Makis A, Hatzimichael E, et al. Treatment of beta-tha-
lassemia patients with recombinant human erythropoietin: ef-
fect on transfusion requirements and soluble adhesion mole-
ecules. Acta Haematol 2004;111:189–95.
4. Alymara V, Bourantas D, Chaidos A, et al. Effectiveness and safe-
ty of combined iron-chelation therapy with deferoxamine and
deferoxiprone. Hematol J 2004;5:475–9.
5. Benetatos L, Alymara V, Vassou A, Bourantas KL. Malignancies
in beta-thalassemia patients: a single-center experience and a concise review of the literature. Int J Lab Hematol 2008;30:167-72.
6. Otrock ZK, Shamseddine AI, Taher AT. Non-Hodgkin disease in beta-thalassemia major. Am J Hematol 2006;81:62-4.
7. Sallam MM, Alsoliman AM, Alahmed HE, Alabdulaali MK. Chronic myelogenous leukemia in sickle cell/beta 0-thalassemia. Indian J Pathol Microbiol 2011;54:597-8.
8. Thapa R, Pal PK, Mukhopadhyay M. Beta thalassemia major and Hodgkin lymphoma. J Pediatr Hematol Oncol 2009;31:462-3.
9. Tozzi-Cecchetti MC, D’Amelio R, Baroni CD. Thalassemia major terminating in a non-Hodgkin B-cell lymphoma: report of a case. Tumori 1979;65:353-7.
10. Schiliò G, Russo A, Marino S, Musumeci S, Russo G. Occurrence of lymphoma with bone marrow involvement in a boy with beta+ thalassaemia major. Clin Lab Haematol 1979;1:325-8.
11. Chehal A, Loutfi R, Taher A. Beta-thalassemia intermedia and non-Hodgkin’s lymphoma. Hemoglobin 2002;26:219-25.
12. Quattrin N, Mastrobouni A, Laudisio FL, Brancaccio V, Pagnini D. Hb Lepore and (haemo-) blastomata. Folia Haematol Int Mag Klin Morphol Blutforsch 1976;103:915-9.
13. Zurlo MG, De Stefano P, Borgna-Pignatti C, et al. Survival and causes of death in thalassaemia major. Lancet 1989;2:27-30.
14. Al-Jam’a AH, Al-Dabbous IA, Al-Khatti AA, Esan FG. Are we underestimating the leukemogenic risk of hydroxyurea. Saudi Med J 2002;23:1411-3.
15. Stevens RG, Jones DY, Miccozi MS, Taylor PR. Body iron stores and the risk of cancer. N Engl J Med 1988;319:1047-52.

Pediatric chronic myeloid leukemia with B-cell lymphoid blast crisis at presentation

TO THE EDITOR: Chronic Myeloid Leukemia (CML) is a rare hematological malignancy accounting for less than 3% of pediatric and adolescent leukemias, with an annual incidence of approximately 1 per million children and young people aged <20 years [1]. The natural history and biology of pediatric CML is similar to those of adult CML and follows a tri-phasic pattern. Approximately 95% of children present with chronic phase CML (CML-CP) and the remainder present in the accelerated phase CML (CML-AP) or in blast crisis (CML-BC) [2]. CML-BC is defined by 20% blasts in the marrow or the presence of extra-medullary blast proliferation [3, 4]. Blast transformation of CML is lymphoid in 30% of cases and myeloid in the remaining 70%. We report the case of a 10-year-old boy who presented with a 6-week history of weight loss and left-sided upper abdominal pain. On examination, he was found to have substantial splenomegaly extending into the right iliac fossa. His full blood count showed a hemoglobin level of 6.6 g/dL, a platelet count of 148x10^9/L, and a total white cell count of 575x10^9/L. A differential count showed the following: blasts, 30%; promyelocytes, 6%; myelocytes, 24%; metamyelocytes, 11%; neutrophils, 7%; eosinophils, 9%; basophils, 3%; monocytes, 1%; and lymphocytes, 10% (Fig. 1). Flow cytometry of the blast population showed that the blasts expressed CD19, c-CD79a, CD10, HLA-DR, CD34, and TdT surface antigens. Chromosome analysis showed a t(9;22)(q34;q11) translocation consistent with a Philadelphia chromosome (Fig. 2A). Interphase fluorescence in situ hybridization (FISH) showed BCR-ABL1 fusion signals in 90% of the nuclei (Fig. 2B). A minor breakpoint cluster region (210 kDa) was confirmed using RT-PCR. In the absence of a documented CML-CP, distinguishing between lymphoid blast crisis of CML and a Philadelphia chromosome-positive ALL can be difficult. A diagnosis of CML in B-cell lymphoid blast crisis rather than de novo precursor B-cell ALL was made because of the concurrent presence of basophilia, a predominance of metamyelocytes and myelocytes, and the p210 BCR-ABL transcript. The patient did not have any additional chromosomal anomalies associated with advanced phase CML and was negative for IgH rearrangement on FISH analysis.

The patient achieved a complete hematological response and a minor cytogenetic response following induction therapy comprising dexamethasone, vincristine, daunorubicin, asparaginase, and imatinib. Nonetheless, he subsequently died of idiopathic pneumonitis after allogeneic stem-cell transplantation.

The progression from CML-CP to CML-BC in the pre-tyrosine kinase era is well described, but CML-BC at presentation in children is extremely rare. The case reported here adds to the literature on the simultaneous presence of features of both lymphoblastic transformation and CML at presentation in the absence of cytogenetic clonal evolution. Further research into the biology of the aggressive phase of CML is required to develop novel targets to improve outcomes.

Fig. 1. Blood film demonstrating chronic myeloid leukemia in lymphoid blast transformation.